Skip to content

Depression research published in 2022

344 studies whose primary subject is depression were published in 2022, up from 247 in 2021. Newest first. Back to the depression overview

Studies

Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?

Pharmaceuticals December 31, 2022 Antonio Munafò, Davide Arillotta, Guido Mannaioni et al. 15 citations

Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation of depressive symptoms. However, to date, there have been several study limitations (e.g., small sample sizes, blinding, limited follow-up,...

Effectiveness of mindfulness-based stress reduction on depression, anxiety, and stress of women with the early loss of pregnancy in southeast Iran: a randomized control trial.

Reproductive health December 29, 2022 Masumeh Nasrollahi, Masumeh Ghazanfar Pour, Atefeh Ahmadi et al.

The loss of the fetus may cause mental health problems in women. The present study aimed to determine the effect of mindfulness-based stress reduction (MBSR) on anxiety, depression, and stress in women with early pregnancy loss. This study was performed on 106 women with early pregnancy loss in Shiraz, Iran. The intervention group underwent eight counselling sessions. Pre-test and post-test...

DOI: 10.1186/s12978-022-01543-2 (opens in new tab) Full text (opens in new tab) Counseling Loss of pregnancy Mental health Mindfulness-based stress reduction

The Potential of Psilocybe Genus Fungi to Treat Depression and Some Addictions

Hop and Medicinal Plants December 28, 2022 Vanessa Eveline Vlaic, Andreea Ona

The therapeutic use of the substance psilocin produced by the fungi from the genus named Psilocybe has been an interesting but also controversial topic of discussion among researchers since the 1950s until now. These fungi can synthesize several alkaloids such as psilocybin, which has hallucinogenic properties, but also muscarine, which is a toxic substance that stimulates that part of the...

DOI: 10.15835/hamp14453 (opens in new tab) Psilocybin Hallucinogen Traditional medicine

The efficacy of mindfulness‐based cognitive therapy to improve depression symptoms and quality of life in individuals with memory difficulties and caregivers: A short report

Alzheimer’s & Dementia: Translational Research & Clinical Interventions December 27, 2022 Lana J. Ozen, Sacha Dubois, Megan M. English et al.

Abstract Introduction Depression symptoms are common for older adults with memory difficulties and their caregivers. Mindfulness‐based cognitive therapy (MBCT) reduces the risk of relapse in recurrent depression and improves depression symptoms. We explored recruitment and retention success and preliminary effect sizes of MBCT on depression and anxiety symptoms, as well as mindfulness facets,...

High dose of psilocybin effective for treatment‐resistant depression

The Brown University Psychopharmacology Update December 27, 2022

Adults with treatment‐resistant depression who received a single 25‐mg dose of psilocybin saw significant improvement in depressive symptoms relative to a control dose at 3 weeks, a Phase 2b trial has found. A smaller 10‐mg dose of psilocybin did not result in significant improvement over the control dose of 1 mg, and adverse events were common in both of the higher‐dose groups. Study results...

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.

Journal of Affective Disorders December 27, 2022 Aki Nikolaidis, Rafaelle Lancelotta, Natalie Gukasyan et al. 24 citations

BackgroundSubjective experiences seem to play an important role in the enduring effects of psychedelic experiences. Although the importance of the subjective experience on the impact of psychedelics is frequently discussed, a more detailed understanding of the subtypes of psychedelic experiences and their associated impacts on mental health has not been well documented.MethodsIn the current...

DOI: 10.1016/j.jad.2022.12.042 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Psychedelic experiences Psychedelic journeys Hallucinogenic experiences +20

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression.

Pharmaceuticals December 26, 2022 Lorena Catarina Del Sant, Luciana Maria Sarin, Ana Cecília Lucchese et al.

Esketamine has been approved by the US Food and Drug Administration (FDA) as an adjunctive treatment for use in conjunction with an oral antidepressant for patients with treatment-resistant depression (TRD), but dissociative symptoms are common adverse effects. A retrospective analysis of 394 subcutaneous esketamine injections given to 70 patients with TRD that were administered once a week...

Depression Improves Following Single Dose of Psilocybin

Psychiatric News December 26, 2022 Nick Zagorski

Back to table of contents Previous article Next article Clinical & ResearchFull AccessDepression Improves Following Single Dose of PsilocybinNick ZagorskiNick ZagorskiPublished Online:26 Dec 2022https://doi.org/10.1176/appi.pn.2023.01.1.50AbstractPatients with treatment-resistant depression who receive a single dose of psilocybin may experience a reduction in depression symptoms.iStock/Rich...

DOI: 10.1176/appi.pn.2023.01.1.50 (opens in new tab) Psilocybin Depression economics Randomized controlled trial Significant difference +1

A comparison of the antianhedonic effects of repeated ketamine infusions in melancholic and non-melancholic depression

Frontiers in Psychiatry December 22, 2022 Wei Zheng, Xin-Hu Yang, Li-Mei Gu et al. 4 citations

ObjectivesMelancholic depression may respond differently to certain treatments. The aim of this study was to compare the antianhedonic effects of six intravenous injections of 0.5 mg/kg ketamine in patients with melancholic and non-melancholic depression, which remain largely unknown.MethodsIndividuals experiencing melancholic (n = 30) and non-melancholic (n = 105) depression were recruited and...

Effect of Mindfulness Breathing Meditation on Depression, Anxiety, and Stress: A Randomized Controlled Trial among University Students

Healthcare December 22, 2022 Maria Komariah, Kusman Ibrahim, Tuti Pahria et al. 74 citations

BACKGROUND: The COVID-19 outbreak has caused various changes in all aspects of human life, including the educational system. These changes have forced students to undertake an adaptive process that has inevitably affected aspects of their life and psychological well-being. Adaptation of learning into online forms in universities, including nursing, triggers depression, stress, and anxiety. The...

Aesthetic chills foster self-acceptance and emotional breakthrough in depression

December 21, 2022 Félix Schoeller, Abhinandan Jain, Vladimir Adrien et al. 10 citations preprint

Aesthetic chills, a strong emotional reaction characterized by a specific bodily response of thermoregulatory mechanisms such as shivers and goosebumps, may hold scientific and clinical potential for reward-related or dopaminergic illnesses. In this first exploratory study, we examined the effects of chills stimulation on subjects clinically diagnosed with depression. Our results suggest that...

DOI: 10.31234/osf.io/rhftq (opens in new tab) Chills Sadness Affect linguistics Psychotherapist +3

Therapeutic and Safety Outcomes of Intravenous Ketamine for Treatment-refractory Depression in a Veteran Population: A Case Series.

Military Medicine December 20, 2022 Grace Vitek, R. Langenfeld, R. Walters et al.

INTRODUCTION Major depressive disorder is a serious, recurrent, and disabling psychiatric illness. Despite many proven treatments with multiple medications or therapies, approximately 30% of patients fail to achieve remission and are considered to have treatment-refractory depression (TRD). Recently, there has been a growing interest in the use of intravenous (IV) ketamine for the treatment of...

Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 20, 2022 John Cook, Angelos Halaris

Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019. It antagonizes the NMDA receptor providing rapid improvement in symptoms with a complex mechanism of action primarily mediated through glutamatergic activation. Significant barriers exist to widespread use of esketamine including durability of response, particularly in the...

(+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission.

European Journal of Pharmacology December 19, 2022 Hugo R Arias, Philippe De Deurwaerdère, Ali El-Kasaby et al.

The antidepressant-like activity of (+)-catharanthine and (-)-18-methoxycoronaridine [(-)-18-MC] was studied in male and female mice using forced swim (FST) and tail suspension tests (TST). The underlying molecular mechanism was assessed by electrophysiological, radioligand, and functional experiments. The FST results showed that acute administration (40 mg/kg) of (+)-catharanthine or (-)-18-MC...

Nightmares and psychiatric symptoms: A systematic review of longitudinal, experimental, and clinical trial studies.

Clinical Psychology Review December 17, 2022 Bryony Sheaves, Stephanie Rek, Daniel K. Freeman

Nightmares occur across a wide range of psychiatric disorders, but outside of PTSD presentations are infrequently considered a treatment priority. We aimed to assess evidence for a contributory causal role of nightmares to the occurrence of psychiatric disorders, and vice versa. A systematic review was conducted of longitudinal, experimental, and clinical trial studies. Twenty-four...

Role of Mindfulness between Early Maladaptive Schemas and Post-Partum Depression: a Ray of Hope

Primenjena psihologija December 16, 2022 Rida Fatima, Alishba Hania, Momal Zafar

Mothers of a newborn face a lot of physical and psychological challenges and early maladaptive schemas play a significant part in determining long-term negative consequences such as post-partum depressive symptoms. This research proposed that mindfulness could play a positive role between the early schemas and post-partum depressive symptoms among new mothers. Data was collected from a sample...

Predictors of stress, anxiety, depression, study engagement and academic performance in physiotherapy students, including a subgroup receiving a mindfulness training program

Focus on Health Professional Education A Multi-Professional Journal December 16, 2022 Janet C. McConville, Richard Chambers, Craig Stephen Hassed et al. 1 citation

Introduction: Student wellbeing is a growing concern for physiotherapy and other health professional students, with potential impacts on academic success, patient care and future personal wellbeing. The purpose of this study was to determine the predictors of future stress, anxiety, depression, study engagement and academic performance in physiotherapy students, including a subgroup who...

The Incidental Resolution of Severe Alcohol Use Disorder during Esketamine Treatment of Major Depressive Disorder: A Case Report.

Case Reports in Psychiatry December 15, 2022 Zeeshan Faruqui, Christopher Kim

Alcohol use disorder (AUD) is especially prevalent among individuals with major depressive disorder (MDD) and is associated with higher morbidity, mortality, disability, and risk for suicide. Intranasal esketamine has been documented to be a safe and effective option for treatment resistant MDD and received US FDA approval in 2019. However, the availability of esketamine is limited due to...

TIAM1-mediated synaptic plasticity underlies comorbid depression–like and ketamine antidepressant–like actions in chronic pain

Journal of Clinical Investigation December 15, 2022 Q. Ru, Yungang Lu, Ali Bin Saifullah et al.

Chronic pain often leads to depression, increasing patient suffering and worsening prognosis. While hyperactivity of the anterior cingulate cortex (ACC) appears to be critically involved, the molecular mechanisms underlying comorbid depressive symptoms in chronic pain remain elusive. T cell lymphoma invasion and metastasis 1 (Tiam1) is a Rac1 guanine nucleotide exchange factor (GEF) that...

Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression

Bipolar Disorders December 14, 2022 Farhan Fancy, Nelson B Rodrigues, Joshua D. Di Vincenzo et al. 35 citations

Abstract Background Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression. Methods This study was conducted in a community clinic in...